A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablursen (ISIS 702843-CS4) Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: 7ddb56f2e5fbe6685c8ed86c8f14c854fcd94b65
First added on: Mar 21, 2025